Targeting tumour hypoxia in breast cancer
Targeting tumour hypoxia in breast cancer
复制标题
DOI：
10.1016/j.ejca.2008.09.025
复制
发表时间：
2008-12-01
影响因子：
8.4
通讯作者：
Harris, Adrian L.
中科院分区：
文献类型：
--
作者：
Milani, Manuela;Harris, Adrian L.
乳腺癌是女性最常见的恶性肿瘤。缺氧发生在乳腺癌和其他实体瘤中，由于肿瘤生长超过现有的脉管系统。缺氧导致由HIF-1（缺氧诱导因子-1）协调的适应性反应，这对肿瘤进展和治疗抵抗至关重要，导致患者预后不良。在一些研究中，HIF-1 α的下游靶点被认为是缺氧标志物。乳腺癌的生物学异质性已经通过基因组分析技术进行了研究。最近的数据表明，治疗结果取决于个人的遗传特征，缺氧签名是一个重要的预后因素。识别具有预测治疗结果潜力的分子生物标志物对于选择患者接受最有益的治疗至关重要，并且在未来可能会推动临床试验中的分层。(C)2008爱思唯尔有限公司保留所有权利。
Breast cancer is the most common malignancy in women. Hypoxia occurs in breast cancer and in other solid tumours due to the tumour outgrowing the existing vasculature. Hypoxia leads to an adaptive response, orchestrated by HIF-1 (hypoxia-inducible factor-1), that is crucial for tumour progression and therapy resistance responsible for poor patient outcome. In several studies, downstream targets of HIF-1 alpha were considered as hypoxia markers. The biological heterogeneity of breast cancer has been investigated through genome profiling technologies. The recent data suggest that treatment outcome depends on individual genetic features and that the hypoxia signature is a significant prognostic factor. The identification of molecular biomarkers with the potential to predict treatment outcome is essential for selecting patients to receive the most beneficial therapy, and in the future may drive stratification in clinical trials. (C) 2008 Elsevier Ltd. All rights reserved.